Phage inhibit pathogen dissemination by targeting bacterial migrants in a chronic infection model

mBio

Volumn 8, Issue 2, 2017, Pages

  Darch, Sophie E ^a   Kragh, Kasper N ^b   Abbott, Evelyn A ^a   Bjarnsholt, Thomas ^b,c   Bull, James J ^a   Whiteley, Marvin ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXOPOLYSACCHARIDE; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOPHAGE; CONTROLLED STUDY; CULTURE MEDIUM; CYSTIC FIBROSIS; DISEASE MODEL; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROBIAL COMMUNITY; MICROSCOPY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; ANTIBIOTIC RESISTANCE; BACTERIOLYSIS; COMPLICATION; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; SPUTUM; THEORETICAL MODEL; VIROLOGY;

ANTI-BACTERIAL AGENTS; BACTERIOLYSIS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL VIABILITY; MODELS, THEORETICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 85019057013     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00240-17     Document Type: Article

References (36)

1. Ventola CL. 2015. The antibiotic resistance crisis; part 1: causes and threats. P T 40:277-283.
2. Chanishvili N. 2012. Phage therapy—history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res 83: 3-40. https://doi.org/10.1016/B978-0-12-394438-2.00001-3.
3. Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. 2009. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53:2469-2474. https://doi.org/10.1128/AAC.01646-08.
4. Saussereau E, Vachier I, Chiron R, Godbert B, Sermet I, Dufour N, Pirnay JP, De Vos D, Carrie F, Molinari N, Debarbieux L. 2014. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect 20:O983-O990. https://doi.org/10.1111/1469-0691.12712.
5. Vinodkumar CS, Kalsurmath S, Neelagund YF. 2008. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol 51:360-366. https:// doi.org/10.4103/0377-4929.42511.
6. Meitert E, Petrovici M, Sima F, Costache G, Savulian C. 1987. Investigation on the therapeutical efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa. Arch Roum Pathol Exp Microbiol 46:17-26.
7. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J. 2006. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17:309-317. https://doi.org/10.3892/ijmm.17.2.309.
8. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096-1104. https://doi.org/ 10.1086/651135.
9. Pamp SJ, Sternberg C, Tolker-Nielsen T. 2009. Insight into the microbial multicellular lifestyle via flow-cell technology and confocal microscopy. Cytometry 75:90-103. https://doi.org/10.1002/cyto.a.20685.
10. Roberts AEL, Kragh KN, Bjarnsholt T, Diggle SP. 2015. The limitations of in vitro experimentation in understanding biofilms and chronic infection. J Mol Biol 427:3646-3661. https://doi.org/10.1016/j.jmb.2015.09.002.
11. Ramsey MM, Whiteley M. 2004. Pseudomonas aeruginosa attachment and biofilm development in dynamic environments. Mol Microbiol 53: 1075-1087. https://doi.org/10.1111/j.1365-2958.2004.04181.x.
12. Shrout JD, Chopp DL, Just CL, Hentzer M, Givskov M, Parsek MR. 2006. The impact of quorum sensing and swarming motility on Pseudomonas aeruginosa biofilm formation is nutritionally conditional. Mol Microbiol 62:1264-1277. https://doi.org/10.1111/j.1365-2958.2006.05421.x.
13. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sorensen SR, Moser C, Kuhl M, Jensen PO, Hoiby N. 2013. The in vivo biofilm. Trends Microbiol 21:466-474. https://doi.org/10.1016/j.tim.2013.06.002.
14. Mc Vay CS, Velasquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938. https://doi.org/10.1128/AAC.01028-06.
15. Palmer KL, Brown SA, Whiteley M. 2007. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J Bacteriol 189:4449-4455. https://doi.org/10.1128/JB.00162-07.
16. Palmer KL, Aye LM, Whiteley M. 2007. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 189:8079-8087. https://doi.org/10.1128/JB.01138-07.
17. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. 2015. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci U S A 112:4110-4115. https://doi.org/10.1073/pnas.1419677112.
18. Kragh KN, Alhede M, Jensen PO, Moser C, Scheike T, Jacobsen CS, Seier Poulsen S, Eickhardt-Sorensen SR, Trostrup H, Christoffersen L, Hougen HP, Rickelt LF, Kuhl M, Hoiby N, Bjarnsholt T. 2014. Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. Infect Immun 82:4477-4486. https://doi.org/10.1128/IAI.01969-14.
19. Connell JL, Wessel AK, Parsek MR, Ellington AD, Whiteley M, Shear JB. 2010. Probing prokaryotic social behaviors with bacterial “lobster traps.” m Bio 1:e00202-10. https://doi.org/10.1128/m Bio.00202-10.
20. Stacy A, Everett J, Jorth P, Trivedi U, Rumbaugh KP, Whiteley M. 2014. Bacterial fight-and-flight responses enhance virulence in a polymicrobial infection. Proc Natl Acad Sci U S A 111:7819-7824. https://doi.org/10.1073/pnas.1400586111.
21. Palmer KL, Mashburn LM, Singh PK, Whiteley M. 2005. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 187:5267-5277. https://doi.org/10.1128/JB.187.15.5267-5277.2005.
22. Hammad A. 1998. Evaluation of alginate-encapsulated Azotobacter chroococcum as a phage-resistant and an effective inoculum. J Basic Microbiol 38:9-16.
23. Hanlon GW. 2007. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30:118-128. https://doi.org/10.1016/j.ijantimicag.2007.04.006.
24. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317-327. https://doi.org/10.1038/ nrmicro2315.
25. Wozniak DJ, Wyckoff TJ, Starkey M, Keyser R, Azadi P, O’Toole GA, Parsek MR. 2003. Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 100:7907-7912. https://doi.org/10.1073/pnas.1231792100.
26. Bjarnsholt T, Kirketerp-Moller K, Jensen PO, Madsen KG, Phipps R, Krogfelt K, Hoiby N, Givskov M. 2008. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 16:2-10. https://doi.org/10.1111/j.1524-475X.2007.00283.x.
27. Connell JL, Ritschdorff ET, Whiteley M, Shear JB. 2013. 3D printing of microscopic bacterial communities. Proc Natl Acad Sci U S A 110: 18380-18385. https://doi.org/10.1073/pnas.1309729110.
28. Wessel AK, Arshad TA, Fitzpatrick M, Connell JL, Bonnecaze RT, Shear JB, Whiteley M. 2014. Oxygen limitation within a bacterial aggregate. m Bio 5:e00992. https://doi.org/10.1128/m Bio.00992-14.
29. Alhede M, Kragh KN, Qvortrup K, Allesen-Holm M, Van Gennip M, Christensen LD, Jensen PO, Nielsen AK, Parsek M, Wozniak D, Molin S, Tolker-Nielsen T, Hoiby N, Givskov M, Bjarnsholt T. 2011. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLo S One 6:e27943. https://doi.org/10.1371/journal.pone.0027943.
30. Ryder C, Byrd M, Wozniak DJ. 2007. Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr Opin Microbiol 10: 644-648. https://doi.org/10.1016/j.mib.2007.09.010.
31. Baker P, Hill PJ, Snarr BD, Alnabelseya N, Pestrak MJ, Lee MJ, Jennings LK, Tam J, Melnyk RA, Parsek MR, Sheppard DC, Wozniak DJ, Howell PL. 2016. Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms. Sci Adv 2:e1501632. https://doi.org/10.1126/sciadv.1501632.
32. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLo S One 6:e16963. https://doi.org/10.1371/journal.pone.0016963.
33. Tan D, Svenningsen SL, Middelboe M. 2015. Quorum sensing determines the choice of antiphage defense strategy in Vibrio anguillarum. m Bio 6:e00627. https://doi.org/10.1128/m Bio.00627-15.
34. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298. https://doi.org/10.1126/science.280.5361.295.
35. Murray JL, Kwon T, Marcotte EM, Whiteley M. 2015. Intrinsic antimicrobial resistance determinants in the superbug Pseudomonas aeruginosa. m Bio 6:e01603-15. https://doi.org/10.1128/m Bio.01603-15.
36. Darch SE, Mc Nally A, Harrison F, Corander J, Barr HL, Paszkiewicz K, Holden S, Fogarty A, Crusz SA, Diggle SP. 2015. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection. Sci Rep 5:7649. https:// doi.org/10.1038/srep07649.